You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

January 26, 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

Pharmacologic treatment of prostate cancer

A review of current pharmacologic therapies and newly approved agents for advanced or metastatic prostate cancer. » ADT, GnRH analogues, antiandrogens, and more

FDA approves renal therapy solution

FDA approved Baxter International's Phoxillum Renal Replacement Solutions (BK4/2.5 and B22K4/0). » Read more on this orphan drug

Continuing Education

MTM opportunities in caring for the patient with cardiovascular disease

This month's CE activity is the last unit of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. Running from February 2014 through January 2015, the series enables pharmacists to earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to empower pharmacists to engage patients with cardiovascular disease in the practices of self-management.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT01-JKF33.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

[BLOG]: Biosimilar confusion and insights

Since Virginia became the first state in May 2013 to enact legislation regulating a pharmacist's substitution of an interchangeable biologic drug for a prescribed reference biologic drug, there has not been much activity or clarity on the issue. » Stakeholder issues

 

RELATED ARTICLES

New frontiers in prostate cancer

FDA drug approvals-January 2015

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group